
## Konrad Futyma

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1372213/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Perioperative and Long-Term Anatomical and Subjective Outcomes of Laparoscopic Pectopexy and Sacrospinous Ligament Suspension for POP-Q Stages Il–IV Apical Prolapse. Journal of Clinical Medicine, 2022, 11, 2215.	1.0	6
2	Platelet Rich Plasma in Gynecology—Discovering Undiscovered—Review. International Journal of Environmental Research and Public Health, 2022, 19, 5284.	1.2	9
3	Predictive value of classification systems and single fistulaâ€related factors in surgical management of vesicovaginal fistula. Neurourology and Urodynamics, 2021, 40, 529-537.	0.8	8
4	Radiation-Induced Recurrent Vesicovaginal Fistula—Treatment with Adjuvant Platelet-Rich Plasma Injection and Martius Flap Placement—Case Report and Review of Literature. International Journal of Environmental Research and Public Health, 2021, 18, 4867.	1.2	1
5	Reliability of the Polish Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) and Assessment of Sexual Function before and after Pelvic Organ Prolapse Reconstructive Surgery—A Prospective Study. Journal of Clinical Medicine, 2021, 10, 4167.	1.0	2
6	Quality of Sexual Life after Native Tissue versus Polypropylene Mesh Augmented Pelvic Floor Reconstructive Surgery. Journal of Clinical Medicine, 2021, 10, 4807.	1.0	0
7	Identification of the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire—IUGA Revised (PISQ-IR) Cutoff Scores for Impaired Sexual Function in Women with Pelvic Floor Disorders. Journal of Clinical Medicine, 2020, 9, 13.	1.0	10
8	Urogynaecological Symptoms among Oncological Survivors and Impact of Oncological Treatment on Pelvic Floor Disorders and Lower Urinary Tract Symptoms. A Six-Month Follow-Up Study. Journal of Clinical Medicine, 2020, 9, 2804.	1.0	7
9	Four-arm polypropylene mesh for vaginal vault prolapse-surgical technique and outcomes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 255, 203-210.	0.5	5
10	Urine Proteomic Study in OAB Patients—Preliminary Report. Journal of Clinical Medicine, 2020, 9, 1389.	1.0	3
11	Sexual function specific questionnaires as a useful tool in management of urogynecological patients – Review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 234, 126-130.	0.5	9
12	Platelet-Rich Plasma as Adjuvant Therapy for Recurrent Vesicovaginal Fistula: A Prospective Case Series. Journal of Clinical Medicine, 2019, 8, 2122.	1.0	17
13	Reply from authors to the Letter to the Editor on RE: Futyma et al. use of uroflow parameters in diagnosing an overactive bladder—Back to the drawing board and ICS News 613. Neurourology and Urodynamics, 2018, 37, 1509-1510.	0.8	0
14	PROSPECT multicenter trial—a real milestone in prolapse surgery?. Neurourology and Urodynamics, 2018, 37, 515-516.	0.8	4
15	Candida lusitaniae – aÂcase report of an intraperitoneal infection. Przeglad Menopauzalny, 2018, 17, 94-96.	0.6	11
16	Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia?. Journal of Clinical Medicine, 2018, 7, 263.	1.0	0
17	Use of uroflow parameters in diagnosing an overactive bladder—Back to the drawing board. Neurourology and Urodynamics, 2017, 36, 198-202.	0.8	12
18	Can botox improve nightâ€ŧime overactive bladder symptoms in women?. Neurourology and Urodynamics, 2017, 36, 648-652.	0.8	10

Konrad Futyma

#	Article	IF	CITATIONS
19	Urinary retention in female OAB after intravesical Botox injection: who is really at risk?. International Urogynecology Journal, 2017, 28, 845-850.	0.7	38
20	Reply from authors to Letter to the Editor on "RE: Konrad Futyma, Åukasz Nowakowski, MichaÅ, Bogusiewicz, Alicja Ziętek, Andrzej P. Wieczorek and Tomasz Rechberger. Use of Uroflow Parameters in Diagnosing an Overactive Bladder—Back to the Drawing Board―manuscript number: Neurourol Urodyn DOI 10.1002/nau.22898. Neurourology and Urodynamics, 2017, 36, 1659-1660.	0.8	1
21	Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB. Neurourology and Urodynamics, 2017, 36, 1564-1569.	0.8	16
22	Biological markers with potential clinical value in endometrial cancer — review of the literature. Ginekologia Polska, 2017, 88, 331-336.	0.3	6
23	Use of free uroflowmetry vs pressure-flow studies in the diagnosis of overactive bladder syndrome in females. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 207, 137-140.	0.5	3
24	Nonabsorbable urethral bulking agent — clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 207, 68-72.	0.5	19
25	Case of spontaneous tubal stump pregnancy after adnexectomy. Journal of Acute Disease, 2016, 5, 172-173.	0.0	2
26	Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery. International Urogynecology Journal, 2016, 27, 393-398.	0.7	24
27	Hysterectomy trends for benign indications over a 15-year period in an academic teaching center in Poland: a retrospective cohort study. Ginekologia Polska, 2016, 87, 411-416.	0.3	1
28	Power morcellation for women undergoing laparoscopic supracervical hysterectomy $\hat{a} \in$ " safety of procedure and clinical experience from 426 cases. Ginekologia Polska, 2016, 87, 546-551.	0.3	3
29	When and how should we treat cesarean scar defect — isthmocoele?. Ginekologia Polska, 2016, 87, 664-668.	0.3	19
30	An Open Multicenter Study of Clinical Efficacy and Safety of Urolastic, an Injectable Implant for the Treatment of Stress Urinary Incontinence: One-Year Observation. BioMed Research International, 2015, 2015, 1-5.	0.9	19
31	Progress on macrophage's proinflammatory products as markers of acute endometriosis. Journal of Acute Disease, 2015, 4, 169-172.	0.0	6
32	A classification of complications in urogynecology. Przeglad Menopauzalny, 2014, 2, 127-131.	0.6	2
33	Expression of genes encoding extracellular matrix proteins: A macroarray study. Oncology Reports, 2014, 32, 2349-2353.	1.2	7
34	Does a midurethral sling inserted at the time of pelvic organ prolapse mesh surgery increase the rate of de novo OAB? A prospective longitudinal study. Ginekologia Polska, 2014, 85, 652-657.	0.3	2
35	Does a midurethral sling inserted at the time of pelvic organ prolapse mesh surgery increase the rate of de novo OAB? A prospective longitudinal study. Ginekologia Polska, 2014, 85, .	0.3	1
36	Self-perceived quality of life after pelvic organ prolapse reconstructive mesh surgery: prospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 108-112.	0.5	4

Konrad Futyma

#	Article	IF	CITATIONS
37	Transvaginal Prolift® mesh surgery due to advanced pelvic organ prolapse does not impair female sexual function: a prospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 165, 295-298.	0.5	16
38	Tape Fixation: An Important Surgical Step to Improve Success Rate of Anti-Incontinence Surgery. Journal of Urology, 2011, 186, 180-184.	0.2	22
39	Tape fixation: an important surgical step to improve success rate of anti-incontinence surgery. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 412-412.	0.7	0
40	Body mass index does not influence the outcome of anti-incontinence surgery among women whereas menopausal status and ageing do: a randomised trial. International Urogynecology Journal, 2010, 21, 801-806.	0.7	55
41	The Clinical Effectiveness of Retropubic (IVS-02) and Transobturator (IVS-04) Midurethral Slings: Randomized Trial. European Urology, 2009, 56, 24-30.	0.9	74
42	Reply to Marco Calcagno, Francesco Plotti, Maria Pastore and Pierluigi Benedetti Panici's Letter to the Editor re: Tomasz Rechberger, Konrad Futyma, Katarzyna Jankiewicz, et al. The Clinical Effectiveness of Retropubic (IVS-02) and Transobturator (IVS-04) Midurethral Slings: Randomized Trial. Eur Urol 2009;56:24-30. European Urology, 2009, 56, e34-e35.	0.9	0
43	Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations. Oncology Reports, 2006, 16, 1041.	1.2	4
44	The prevalence of mtDNA4977 deletion in primary human endometrial carcinomas and matched control samples. Oncology Reports, 1994, 20, 683.	1.2	4